Barriers and determinants of consistent offering of HPV vaccination by healthcare facilities-Reference-Cited by-同舟云学术

Barriers and determinants of consistent offering of HPV vaccination by healthcare facilities

Published:2023-08 Issue:2 Volume:19 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Osaghae Ikponmwosa¹,Chido-Amajuoyi Onyema Greg¹,Khalifa Banda A. A.²,Shete Sanjay¹³⁴^ORCID

Affiliation:

1. Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

3. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

4. Division of Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Funder

National Cancer Institute

Betty B. Marcus Chair in Cancer Prevention

Duncan Family Institute for Cancer Prevention and Risk Assessment

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2023.2264596

Reference49 articles.

1. Centers for Disease Control and Prevention. Cancers associated with human papillomavirus United States—2015–2019. USCS data brief no 32. Atlanta GA: Centers for Disease Control and Prevention US Department of Health and Human Services Web site; Updated 2022 [accessed 2023 Jun]. https://www.cdc.gov/cancer/uscs/about/data-briefs/no31-hpv-assoc-cancers-UnitedStates-2015-2019.htm.

2. Economic Value of Lost Productivity Attributable to Human Papillomavirus Cancer Mortality in the United States

3. Centers for Disease Control and Prevention. Human papillomavirus: HPV infection. CDC website web site; Updated 2023. [accessed 2023 Jun]. https://www.cdc.gov/hpv/parents/about-hpv.html.

4. Estimates of the annual direct medical costs of the prevention and treatment of disease associated with human papillomavirus in the United States

5. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009–2015